CLAIMS

1. Use of a combination in the manufacture of a medicament for the treatment, prevention, stabilisation, delay in onset and/or reduction of the symptoms of age-related and/or degenerative diseases in a subject, wherein the combination comprises:

- metformin, and/or an N-oxide, a hydrate, a pharmaceutically acceptable salt or solvate thereof, and

- an acetylcholinesterase inhibitor, and/or an N-oxide, a hydrate, a pharmaceutically acceptable salt or solvate thereof, wherein the acetylcholinesterase inhibitor is selected from the group comprising: galantamine, donepezil, rivastigmine and memantine;

and wherein the age-related and/or degenerative diseases are diseases of the neuro-musculoskeletal system or frailty, wherein said disease is characterized by impaired locomotor activity.

2. The use according to any of the preceding claims wherein the age-related and/or degenerative diseases of the neuro-musculoskeletal system are selected from the group comprising extrapyramidal and movement disorders, diseases of myoneural junction and muscle, systemic atrophies primarily affecting the central nervous system, muscular dystrophy, duchenne muscular dystrophy, spinal muscular atrophy, motor neuron diseases such as amyotrophic lateral sclerosis, abnormal involuntary movements, abnormalities of gait and mobility, ataxia, and sarcopenia.

3 The use according to any of the preceding claims wherein the age-related and/or degenerative diseases of the neuro-musculoskeletal system are extrapyramidal and movement disorders, diseases of myoneural junction and muscle, systemic atrophies primarily affecting the central nervous system, muscular dystrophy, duchenne muscular dystrophy, spinal muscular atrophy, motor neuron diseases such as amyotrophic lateral sclerosis, abnormal involuntary movements, abnormalities of gait and mobility, or ataxia.

4. The use according to claim 1 to 2 wherein the age-related and/or degenerative disease of the neuro-musculoskeletal system is sarcopenia.

5. The use according to claim 1 wherein the age-related and/or degenerative diseases of the neuro-musculoskeletal system are mitochondrial associated neuromusculoskeletal diseases selected from central core disease and Optic Atrophy 1 (OPA1) associated diseases, wherein said OPA1 associated diseases are selected from optic atrophy, OPA1 associated hypertension, and OPA1 associated atrophy.

6. The use according to any of the preceding claims , wherein the acetylcholinesterase inhibitor is galantamine.

7. Non-therapeutic use of a combination for prevention, stabilization and/or reduction of age-related complaints and/or degenerative complaints in a subject, said combination comprising:

- metformin, or an N-oxide, a hydrate, a pharmaceutically acceptable salt or solvate thereof, and

- an acetylcholinesterase inhibitor, or an N-oxide, a hydrate, a pharmaceutically acceptable salt or solvate thereof, wherein the acetylcholinesterase inhibitor is selected from the group comprising: galantamine, donepezil, rivastigmine, and memantine; and

wherein the age-related complaints and/or degenerative complaints are selected from the group comprising muscular weakness, decreased muscular strength, neuro-muscular degeneration, and impaired mobility.

8. Non-therapeutic use of a combination for improving a measure of life span and/or health span in a subject, said combination comprising:

metformin, or an N-oxide, a hydrate, a pharmaceutically acceptable salt or solvate thereof, and

- an acetylcholinesterase inhibitor, an N-oxide, a hydrate, a pharmaceutically acceptable salt or solvate thereof, wherein the acetylcholinesterase inhibitor is galantamine, and

wherein the improved measure of life span and/or health span is selected from the group comprising the mitigation or stabilisation of age-related complaints, relative to the condition of the subject before administration of the combination or relative to a control population, and wherein age-related complaints and/or degenerative complaints are selected from the group comprising muscular weakness, decreased muscular strength, neuro-muscular degeneration, impaired mobility.

9. The non-therapeutic use of the combination according to claim 7, wherein the acetylcholinesterase inhibitor is galantamine.

10. The use according to any one of claims 1 to 6, or the non-therapeutic use of the combination according to any one of claims 7 to 9, wherein the biguanide and the acetylcholinesterase inhibitor are to be administered in a subtherapeutic dose to the subject.

11. The use according to any one of claims 1 to 6 or the non-therapeutic use of the combination according to anyone of claims 7 to 9, wherein said subject is a human subject.